OVERVIEW
LightOx is headquartered in Newcastle upon Tyne, UK and is developing new light activated drug compounds. We are targeting a treatment for early stage and pre-cancerous lesions and are currently completing pre-clinical testing.
Our lead candidate will enter Phase I/IIa study for the treatment of early-stage oral cancer lesions in 2025 with our clinical team in Liverpool, UK. With an IP portfolio consisting of five global patents, and a vibrant team experienced in the development of novel therapeutics, LightOx has a solid scientific and commercial base and looks to create a range of treatments from its platform technology.
We are exploring projects and applications that spread beyond oncology targets, with the technology demonstrated in bacterial, fungal and plant species.
OUR SOLUTION
LXD191
LightOx are developing a new class of light activated chemotherapy for the treatment of oral cancer. We use photosensitising agents along with light to kill cancer cells.
LEARN MORE